Are you Dr. Lauring?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 38 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
650 W 168th St
Bb-1427 Dept Pathology Columbia University
New York, NY 10032Phone+1 212-305-0395Fax+1 212-305-5498
Summary
- Dr. Brett Lauring, MD is a board certified pathologist in New York, New York. He is currently licensed to practice medicine in New York.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Pathology-Anatomic and Clinical, 1996 - 2001
New York University School of MedicineClass of 1996
Certifications & Licensure
NY State Medical License 1997 - 2021- American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- 130 citationsRecognition of C-terminal amino acids in tubulin by pore loops in Spastin is important for microtubule severingSusan Roehl White, Katia J. Evans, Jeffrey W. Lary, James L. Cole, Brett Lauring
The Journal of Cell Biology. 2007-03-26 - 44 citationsLong-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.Silvina Gallo, Bernard Charbonnel, Allison Goldman, Harry Shi, Susan Huyck
Diabetes, Obesity & Metabolism. 2019-04-01 - 61 citationsLong‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension studyRonnie Aronson, Juan P. Frias, Allison Goldman, Amanda Darekar, Brett Lauring
Diabetes, Obesity & Metabolism. 2018-02-23
Press Mentions
Kallyope Inc. Appoints Brett Lauring as Chief Medical OfficerFebruary 5th, 2019
Kallyope Enters Phase 2 with First-in-Class Oral Approach for the Treatment of Both Obesity and Type 2 DiabetesSeptember 28th, 2023- Kallyope to Expand Its Metabolic Disorder Programme GloballyOctober 26th, 2023
